# Neurocrine Biosciences, Inc. (NBIX): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Neurocrine Biosciences, Inc. (NBIX) is 84/100, ranked against 24,000+ stocks in 35 markets (Quality 78, Value 44, Momentum 60, each scored against its sector).

- StockRank: 84/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 78, Value 44, Momentum 60: each a 0-100 percentile within Healthcare.
- Position: #4,266 overall, #475 in Healthcare.
- Listing: United States, NMS; Healthcare / Drug Manufacturers - Specialty & Generic.
- Last close: 145.87 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors sold USD 63.3M.
- Buybacks, last 180 days: the company bought back USD 233.7M on 2 days.

Source: https://moatmap.ai/stock/NBIX
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker